American Kidney Fund

According to the American Kidney Fund (AKF) audit of December 31, 2020 (Note 12, In-Kind Contributions), AKF received donated in-kind contributions in 2020 on which it placed a total value of $892,786.

[Note: CharityWatch generally excludes the value of in-kind (non-cash) donations of goods and services from its calculations of Program % and Cost to Raise $100. More information on how grades are calculated and the treatment of in-kind donations can be found on the Our Process page.]

According to the American Kidney Fund (AKF) audit of December 31, 2020 (Note 10, Public Support):

"During 2020 and 2019, AKF continued its tradition of broad-based public support with approximately 70,000 and 63,000 active contributors, respectively. AKF received public support from two corporations in the amount of $286,287,862, and $273,641,183 for 2020 and 2019, respectively. These contributions represented 85% of the total support and revenue as of December 31, 2020 and 2019."

According to the American Kidney Fund (AKF) audit of December 31, 2020 (Note 9, Paycheck Protection Program Loan):

"On May 5, 2020, AKF received proceeds in the amount of $1,540,500 to fund payroll, rent, utilities, and interest on mortgages and existing debt through the Paycheck Protection program (the PPP Loan). The PPP loan could be forgiven by the U.S. Small Business Administration (SBA) subject to certain performance barriers as outlined in the loan agreement and the CARES Act. As of December 31, 2020, the SBA has formally forgiven the entire portion of AKF's obligation under this PPP loan. Therefore, AKF recognized $1,540,500 of contributions revenue for the year ended December 31, 2020."

According to the American Kidney Fund (AKF) audit of December 31, 2020 (Note 17, Risks and Uncertainties):

"AKF invests in various investment securities. Investment securities are exposed to various risks, such as interest rate, market, and credit risks. Due to the level of risk associated with certain investment securities, it is at least reasonably possible that changes in the values of investment securities will occur in the near term and those changes could materially affect the amounts reported in the [audited] statements of financial position and activities.

"The US District Court, Central District of California granted a preliminary injunction preventing California law AB 290 from becoming law on December 30, 2019. The impact on future grant assistance is unknown pending a trial on the merits. The trial was originally scheduled for mid-July 2020 but delayed due to the pandemic."

According to the American Kidney Fund (AKF) audit of December 31, 2020 (Note 17, Risks and Uncertainties, COVID-19 Pandemic):

"During the year ended December 31, 2020, the World Health Organization declared the spread of the coronavirus disease (COVID-19) a worldwide pandemic. The COVID-19 pandemic is having significant effects on global markets, nonprofits, businesses, and communities. Specific to AKF, COVID-19 may impact various parts of its FY21 operations and financial results, including, but not limited to, reductions in certain revenue streams as well as increases in expenses. As of March 24, 2021, the amount and likelihood of loss relating to these events is not determined and cannot be reasonably estimated as these events are still developing."

According to the American Kidney Fund (AKF) 2020 tax filing, AKF includes in its reporting for Compensation Information re: Officers, Directors, Trustees, Key Employees, and Highest Compensated Employees "Bonus & incentive compensation" paid to seven individuals, including $127,875 paid to Lavarne A. Burton, ex-Officio President & Chief Executive Officer. The reported total compensation in 2020 for Burton is $751,436. The other reported "Bonus & incentive compensation" amounts range from $61,000 to $36,550 (IRS Form 990, Schedule J, Part II).